Verve Therapeutics (VERV) Stock Price, News & Analysis

Company Overview

Verve Therapeutics is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies to address cardiovascular disease. Founded in 2018, the company applies its proprietary base-editing platform to introduce targeted, permanent changes to genes involved in lipid metabolism. By harnessing CRISPR-derived technology, Verve aims to reduce lifelong risk of heart attack and stroke through a one-time therapy designed to lower levels of atherogenic lipoproteins.

The company’s lead program, VERVE-101, targets the PCSK9 gene to achieve sustained reductions in low-density lipoprotein cholesterol (LDL-C). Preclinical studies have demonstrated durable editing of hepatocytes and dose-dependent decreases in circulating LDL-C, setting the stage for initial human trials. Verve’s pipeline also includes discovery-stage programs aimed at ANGPTL3 and other targets implicated in dyslipidemia and cardiovascular risk, underscoring its broader commitment to gene editing as a transformative approach for chronic diseases.

Headquartered in Cambridge, Massachusetts, Verve Therapeutics operates research facilities in the heart of the U.S. biotech corridor. Its scientific team draws on expertise in molecular biology, genomics and cardiovascular medicine, while collaborations with academic institutions and clinical partners support both preclinical development and the design of upcoming clinical studies. The company’s strategic focus remains on rigorous safety evaluation and regulatory engagement to advance its therapies toward potential regulatory approval.

Leadership at Verve includes co-founder and CEO Sekar Kathiresan, a cardiologist and geneticist with a track record in cardiovascular genetics research. The management team comprises seasoned professionals in drug development, clinical operations and regulatory affairs, supported by a board of directors featuring experts in biotechnology investment and translational science. Together, they aim to translate cutting-edge gene editing innovations into durable therapies for patients at risk of cardiovascular events worldwide.

Key Stats

• Today's Range: $11.13 to $11.29
• 50-Day Range: $4.16 to $11.38
• 52-Week Range: $2.86 to $11.41
• Volume: 2.47 million shs
• Average Volume: 2.45 million shs
• Market Capitalization: $992.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.57
• Consensus Rating: Hold

Verve Therapeutics Stock Analysis - MarketRank™

Verve Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 294th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Verve Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Verve Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verve Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verve Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Verve Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

27.37% of the float of Verve Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Verve Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Verve Therapeutics has recently decreased by 9.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verve Therapeutics does not currently pay a dividend.

Dividend Growth

Verve Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

27.37% of the float of Verve Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Verve Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Verve Therapeutics has recently decreased by 9.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.26

News Sentiment

Verve Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Verve Therapeutics this week, compared to 7 articles on an average week.

Search Interest

14 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.

MarketBeat Follows

5 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Verve Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERV Stock Analysis - Frequently Asked Questions

How have VERV shares performed this year?

Verve Therapeutics' stock was trading at $5.64 at the beginning of 2025. Since then, VERV shares have increased by 97.3% and is now trading at $11.13.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. The business earned $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative trailing twelve-month return on equity of 35.81%.

When did Verve Therapeutics IPO?

Verve Therapeutics (VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verve Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VERV
• CIK: 1840574
• Web: vervetx.com
• Phone: 617-603-0070
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Verve Therapeutics: $14.57
• High Price Target: $24.00
• Low Price Target: $11.00
• Potential Upside/Downside: +30.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.71 million
• Net Margins: -303.64%
• Pretax Margin: -303.10%
• Return on Equity: -35.81%
• Return on Assets: -27.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.84
• Quick Ratio: 9.84

Sales & Book Value

• Annual Sales: $32.33 million
• Price / Sales: 30.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.83 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 89,140,000
• Free Float: 71,938,000
• Market Cap: $992.13 million
• Optionable: Optionable
• Beta: 2.23